Eli Lilly joins $1 trillion market capitalization club

Eli Lilly has reached a market value of $1 trillion, becoming the first drugmaker in this exclusive club, largely due to the rapid growth of the weight-loss drug market. The company’s stock surged over 35% this year, fueled by its obesity treatments, Mounjaro and Zepbound, which have outperformed rival Novo Nordisk. With obesity drugs projected to be a $150 billion market by 2030, investors are optimistic about Lilly’s future, especially with the anticipated approval of its oral obesity drug, orforglipron. However, analysts remain cautious about sustaining growth amidst potential price pressures on its existing drugs.

Want More Context? 🔎